

Fabrizio Condorelli

PERSONAL DATA

Born in Catania, April 4th 1972

Resident in Novara

BIO AND EDUCATION

Graduation from Scientific High School in 1990, MD graduation in 1996, in 1995 "visiting scientist" of the "Cardiovascular Department" at Genentech Inc. in San Francisco, USA, under the direction of Dr. Ferrara. In 1999 he became a PhD in Neurobiology after an experience in the years 1998-2000, as a "post-doc" in the laboratory of Prof. Calabretta, Dept of Microbiology, "Kimmel Cancer Center" of Thomas Jefferson University (Philadelphia, PA, USA). Since the beginning of His academic career at Università del Piemonte Orientale, He holds courses of "Cellular and Molecular Pharmacology" (degree in CTF) and "Chemotherapy" (degree in Pharmacy). The expertise of Professor Condorelli in the most modern techniques of cellular and molecular biology, flow cytometry and confocal microscopy is documented by 28 publications regarding different aspects of cell biology, all of which published in international "peer reviewed" journals.

BIBLIOMETRICS

PUBLICATIONS: 28

H-INDEX: 15

IF: AVERAGE 6.03 (168.88 AGGREGATE)

CITATIONS: 3012 (107.57 AVERAGE)

UNIVERSITY CAREER

| | |
|-----------|---|
| 2012- | Associate Professor, Università del Piemonte Orientale |
| 2000-2012 | Adjunct Professor, Università del Piemonte Orientale |
| 1998-2000 | "Post-doctorate fellow", Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, USA |

UNIVERSITY POSITIONS

| | |
|-------|---|
| 2015- | Director of the School of Qualification in Hospital Pharmacy, Università del Piemonte Orientale |
|-------|---|

SCIENTIFIC POSITIONS

| | |
|-------|---|
| 2015- | "Associate Editor" of the journal "Infectious Diseases and Tropical Medicine" |
|-------|---|

| | |
|-------|--|
| 2010- | Referee for the evaluation of "PRIN" and "Future in Research-FIRB" grants from Italian Ministry of Research and University (MIUR) |
| 2009- | Referee of international "peer-reviewed" journals: "Cell Death and Differentiation", "Cell Death in Disease", "PloseONE", "European Journal of Cancer", "Current Medicinal Chemistry", "Oncotargets", "Biomarkers", "Frontiers in Pharmacology". |

MAIN FIELDS OF INTEREST

1. Apoptosis
2. Autophagy
3. Anti-cancer chemotherapy
4. HIV
5. Protein acetylation

CURRENT ISSUES OF RESEARCH

1. Functional characterization of non-receptor kinase Fes in human neuroblastoma

Abstract – Fes is a non-receptor tyrosine kinase with known function only in the cellular components of the "innate" immune response. Nonetheless, the expression of this protein was documented in other cellular types, including neurons and their progenitors, neuroblasts. Objective of this project is to verify the expression/activation of Fes in light of its role in the outbreak of neuroblastoma, the most common solid tumor of childhood.

2. New Therapeutic Strategies in the Treatment of Philadelphia-positive (Ph+) Chronic Myeloid Leukemia (CML)

Abstract – Ph+ CML is consequent to the activation of the chimeric tyrosine kinase BCR-ABL. Although selective inhibitors of BCR-ABL are clinically effective, drug resistance frequently occurs and development of alternative therapeutic strategies is needed. The aim of this project is to verify the role of AMPK and mTOR kinases, as well as of the regulator of gene transcription β -catenin, in "self-renewal" of the leukemia stem cell, in view of their pharmacological targeting.

3. New pharmacological approaches for inhibiting integration and/or re-activation of HIV viral chromosome in the genome of the host cell

Abstract – Therapy of AIDS is mainly based on drugs that interfere with molecular targets encoded by HIV. The ability of the virus to remain integrated into the host genome in "silent" mode is the most profitable strategy of drug evasion. Objective of this project is to verify, in the therapeutic perspective, if the enzymes involved in chromatin remodelling play an important role in the processes of integration and/or re-expression of the viral genome.

CURRENT FUNDED PROJECTS

| PROGRAMME | FUNDED PROJECT |
|--------------------------------|--|
| Intramural Research Grant 2016 | Università del Piemonte Orientale– <u>“Pharmacological modulation of sirtuins for the inhibition of integration and/or reactivation of the viral genome in HIV infections”</u> |
| GILEAD AWARD | GILEAD INC. – <u>“Study ASTROCYTES: Effects and intracellular PK of anti-retroviral drugs onto astrocytes: in vitro and in vivo observations”</u> |

TOP FIVE PAPERS

1. Billington RA, Genazzani AA, Travelli C, Condorelli F. NAD depletion by FK866 induces autophagy. *Autophagy*. 2008 May-Jun;4(3):385-7. ***I.F.: 6.664 Cit: 41***
2. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. *Br J Pharmacol*. 2008 Feb;153(4):657-68. ***I.F.:4.925 Cit: 59***
3. Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. *Nat Genet*. 2002 Jan;30(1):48-58. ***I.F.: 35.532 Cit: 207***
4. Condorelli F, Salomoni P, Cotteret S, Cesi V, Srinivasula SM, Alnemri ES, Calabretta B. Caspase cleavage enhances the apoptosis-inducing effects of BAD. *Mol Cell Biol*. 2001 May;21(9):3025-36. ***I.F.: 9.836 Cit: 93***
5. Salomoni P, Condorelli F, Sweeney SM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. *Blood*. 2000 Jul 15;96(2):676-84. ***I.F.:10.896 Cit: 58***